Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.68 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ATF4 | P18848 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL473429 | 1.00 | NPSR1 (0.68) | NPSR1SMYD3ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL20421744 | 0.98 | NPSR1 (0.66) | NPSR1SMYD3ALDH1A1MEN1KMT2A | |
| SCHEMBL2090052 | 0.90 | — | — | |
| Carbamic Acid SCHEMBL11200157 | 0.87 | NPSR1 (0.70) | NPSR1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL12425654 | 0.83 | NPSR1 (0.70) | NPSR1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL14492244 | 0.83 | NPSR1 (0.70) | NPSR1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL22651967 | 0.83 | NPSR1 (0.70) | NPSR1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL13130101 | 0.83 | NPSR1 (0.70) | NPSR1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL2091865 | 0.82 | NPSR1 (0.96) | NPSR1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2092328 | 0.82 | NPSR1 (0.89) | NPSR1ALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331877-B1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2021-09-22 | — | — | EP | disclosed |
| US-20210251992-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-08-19 | — | — | US | disclosed |
| US-10960003-B2 | Pyrazole pyrimidine derivative and uses thereof | BIOTHERYX, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10376511-B2 | Pyrazole pyrimidine derivative and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-08-13 | — | — | US | disclosed |
| US-20180214447-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. ISRAELI COMPANY, OF (IL) | 2018-08-02 | — | — | US | disclosed |
| US-20180214447-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. ISRAELI COMPANY, OF (IL) | 2018-08-02 | — | — | US | disclosed |
| WO-2017021969-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-02-09 | — | — | WO | disclosed |
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| WO-2008028860-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10960003-B2 | Pyrazole pyrimidine derivative and uses thereof | IRAK1, IRAK2, IRAK3 | NPSR1 4090/4885SMYD3 3792/4885ALDH1A1 1217/4885 |
| US-20210251992-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | IRAK1, IRAK2, IRAK3 | NPSR1 4090/4885SMYD3 3792/4885ALDH1A1 1217/4885 |
| US-10376511-B2 | Pyrazole pyrimidine derivative and uses thereof | IRAK1, IRAK2, IRAK3 | NPSR1 4090/4885SMYD3 3792/4885ALDH1A1 1217/4885 |
| US-20180214447-A1 | PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOF | IRAK1, IRAK2, IRAK3 | NPSR1 4090/4885SMYD3 3792/4885ALDH1A1 1217/4885 |
| US-20080103142-A1 | Benzotriazole kinase modulators | CDK1, CDK3, MAPK1 | NPSR1 2610/4885SMYD3 1933/4885ALDH1A1 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.